evaluation of mebendazole and Ran GTPase inhibition in breast cancer model system.

To investigate the therapeutic potential of mebendazole (MBZ)-loaded nanostructured lipid carriers (NLCs). NLC-MBZ was prepared and characterized to evaluate the and anticancer effects and the inhibitory effect on RanGTP and its potential as an antimetastatic treatment . NLC-MBZ exhibited a size and charge of 155 ± 20 nm and -27 ± 0.